KINASE INHIBITOR-1 NO FURTHER A MYSTERY

Exploring the part of kinases has not simply aided advance the field of cancer biology but also led to the appearance of ‘qualified therapy’ or ‘individualized drugs’ in cancer leading to a paradigm change in cancer therapy.The impressive outcomes shown with imatinib mesylate (aka Gleevec) concentrating on break position cluster (Bcr)-Abels